27553875|t|Estimation of the HIV-1 backward mutation rate from transmitted drug-resistant strains
27553875|a|One of the serious threats facing the administration of antiretroviral therapy to human immunodeficiency virus (HIV-1) infected patients is the reported increasing prevalence of transmitted drug resistance. However, given that HIV-1 drug-resistant strains are often less fit than the wild-type strains, it is expected that drug-resistant strains that are present during the primary phase of the HIV-1 infection are replaced by the fitter wild-type strains. This replacement of HIV-1 resistant mutations involves the emergence of wild-type strains by a process of backward mutation. How quickly the replacement happens is dependent on the class of HIV-1 mutation group. We estimate the backward mutation rates and relative fitness of various mutational groups known to confer HIV-1 drug resistance. We do this by fitting a stochastic model to data for individuals who were originally infected by an HIV-1 strain carrying any one of the known drug resistance -conferring mutations and observed over a period of time to see whether the resistant strain is replaced. To do this, we seek a distribution, generated from simulations of the stochastic model, that best describes the observed (clinical data) replacement times of a given mutation. We found that Lamivudine/Emtricitabine -associated mutations have a distinctly higher, backward mutation rate and low relative fitness compared to the other classes (as has been reported before) while protease inhibitors -associated mutations have a slower backward mutation rate and high relative fitness. For the other mutation classes, we found more uncertainty in their estimates.
27553875	18	23	HIV-1	T005	C0019704
27553875	24	32	backward	T082	C0439784
27553875	33	46	mutation rate	T080	C3178846
27553875	52	78	transmitted drug-resistant	T038	C0013203
27553875	79	86	strains	T001	C1518614
27553875	106	113	threats	T078	C0749385
27553875	143	165	antiretroviral therapy	T061	C1963724
27553875	169	197	human immunodeficiency virus	T005	C0019704
27553875	199	204	HIV-1	T005	C0019704
27553875	206	214	infected	T047	C2363741
27553875	215	223	patients	T101	C0030705
27553875	240	261	increasing prevalence	T081	C1512456
27553875	265	292	transmitted drug resistance	T038	C0013203
27553875	314	319	HIV-1	T005	C0019704
27553875	320	334	drug-resistant	T038	C0013203
27553875	335	342	strains	T001	C1518614
27553875	371	380	wild-type	T028	C1883559
27553875	381	388	strains	T001	C1518614
27553875	410	424	drug-resistant	T038	C0013203
27553875	425	432	strains	T001	C1518614
27553875	461	468	primary	T080	C0205225
27553875	469	474	phase	T079	C0205390
27553875	482	497	HIV-1 infection	T047	C2363741
27553875	502	510	replaced	T169	C0559956
27553875	525	534	wild-type	T028	C1883559
27553875	535	542	strains	T001	C1518614
27553875	549	560	replacement	T169	C0559956
27553875	564	579	HIV-1 resistant	T033	C1836231
27553875	580	589	mutations	T045	C0026882
27553875	616	625	wild-type	T028	C1883559
27553875	626	633	strains	T001	C1518614
27553875	639	646	process	T067	C1522240
27553875	650	658	backward	T082	C0439784
27553875	659	667	mutation	T045	C0026882
27553875	685	696	replacement	T169	C0559956
27553875	708	717	dependent	T169	C3244310
27553875	734	739	HIV-1	T005	C0019704
27553875	740	748	mutation	T045	C0026882
27553875	749	754	group	T078	C0441833
27553875	772	780	backward	T082	C0439784
27553875	781	795	mutation rates	T080	C3178846
27553875	828	838	mutational	T045	C0026882
27553875	839	845	groups	T078	C0441833
27553875	862	867	HIV-1	T005	C0019704
27553875	868	883	drug resistance	T038	C0013203
27553875	909	925	stochastic model	T062	C0871922
27553875	929	933	data	T078	C1511726
27553875	938	949	individuals	T098	C0237401
27553875	970	978	infected	T033	C0439663
27553875	985	990	HIV-1	T005	C0019704
27553875	991	997	strain	T001	C1518614
27553875	1028	1043	drug resistance	T038	C0013203
27553875	1056	1065	mutations	T045	C0026882
27553875	1086	1100	period of time	T201	C3259132
27553875	1120	1129	resistant	T169	C0332325
27553875	1130	1136	strain	T001	C1518614
27553875	1140	1148	replaced	T169	C0559956
27553875	1172	1184	distribution	T169	C1704711
27553875	1201	1212	simulations	T062	C0679083
27553875	1220	1236	stochastic model	T062	C0871922
27553875	1262	1270	observed	T169	C1441672
27553875	1272	1285	clinical data	T170	C1516606
27553875	1287	1298	replacement	T169	C0559956
27553875	1299	1304	times	T081	C1632851
27553875	1316	1324	mutation	T045	C0026882
27553875	1340	1364	Lamivudine/Emtricitabine	T109,T195	C1977395
27553875	1377	1386	mutations	T045	C0026882
27553875	1413	1421	backward	T082	C0439784
27553875	1422	1435	mutation rate	T080	C3178846
27553875	1444	1452	relative	T080	C0205345
27553875	1453	1460	fitness	T056	C1456706
27553875	1483	1490	classes	T170	C0456387
27553875	1527	1546	protease inhibitors	T121	C0033607
27553875	1559	1568	mutations	T045	C0026882
27553875	1583	1591	backward	T082	C0439784
27553875	1592	1605	mutation rate	T080	C3178846
27553875	1615	1623	relative	T080	C0205345
27553875	1624	1631	fitness	T056	C1456706
27553875	1647	1655	mutation	T045	C0026882
27553875	1656	1663	classes	T170	C0456387
27553875	1700	1709	estimates	T081	C0750572